Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Operations (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Cash from Operations data on record, last reported at 69488000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 21.08% year-over-year to 69488000.0; the TTM value through Dec 2025 reached 322980000.0, down 17.49%, while the annual FY2025 figure was 322980000.0, 17.49% down from the prior year.
  • Cash from Operations reached 69488000.0 in Q4 2025 per SNDX's latest filing, up from 70535000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 100709000.0 in Q4 2021 and bottomed at 95162000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 43151400.0, with a median of 41640000.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: soared 744.29% in 2021, then crashed 122.73% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 100709000.0 in 2021, then plummeted by 122.73% to 22894000.0 in 2022, then crashed by 80.61% to 41349000.0 in 2023, then tumbled by 38.79% to 57388000.0 in 2024, then decreased by 21.08% to 69488000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 69488000.0 in Q4 2025, 70535000.0 in Q3 2025, and 87795000.0 in Q2 2025.